Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with Chongqing Pharmaceutical Holdings Co., Ltd. (Genertec CQ Pharma). The partnership aims to integrate complementary strengths and expand collaboration across multiple areas. By enhancing operational efficiency and reducing overall costs, both parties seek to unlock new opportunities for mutual growth and inject strong momentum into business expansion. Furthermore, the two parties will join hands to accelerate the global commercialization of domestically developed innovative drugs, delivering more high-quality medicines to patients worldwide and creating broader social value. Senior leaders from both sides attended the signing ceremony. Representing Genertec CQ Pharma were Quan Yuan, Secretary of the Party Committee and Chairman; Wei Liu, Deputy Secretary of the Party Committee and President; Shaohong Li, Member of the Party Committee and Senior Vice President; and Yihai Chen, Member of the Party Committee and Deputy General Manager. From Henlius were Kurt Yu, Chief Commercial Officer and Senior Vice President, and Susie Liu, Deputy General Manager, Distribution Management.
Under the agreement, the two parties will deepen strategic synergies across areas including channel expansion, marketing management and promotion, market access, and terminal coverage. The collaboration will prioritize enhancing drug accessibility in county-level markets. Leveraging Genertec CQ Pharma's extensive and deeply penetrated national distribution network and retail outlets, the partners will jointly explore and establish a patient-centric new retail model and extended services. Furthermore, the two sides will strengthen collaboration in emerging areas such as logistics and warehousing, supply chain optimization, and internet-based healthcare. These efforts aim to enhance the efficiency and resilience of drug supply through multi-dimensional approaches, while also exploring potential synergies for global expansion, with the goal of benefiting a broader patient population.
Kurt Yu, Chief Commercial Officer, and Senior Vice President of Henlius, commented, “We remain committed to providing high-quality biologic medicines to patients worldwide. The strategic partnership with Genertec CQ Pharma represents a significant milestone in accelerating this mission. By leveraging our combined synergies, we will enhance the delivery of advanced therapies to more patients efficiently — generating both societal and commercial value while better addressing patient needs and advancing public health.”
Quan Yuan, Secretary of the Party Committee and Chairman of Genertec CQ Pharma, stated, “This signing not only marks the entry of both parties into a new phase of collaboration but also represents a crucial milestone in integrating the entire industrial chain — from innovative R&D and distribution to clinical access. Genertec CQ Pharma will leverage its comprehensive channel network and end-to-end service capabilities to accelerate the delivery of high-quality medicines to the clinical frontline. We look forward to working in concert with joined forces, complementing each other’s resources to achieve mutual success and contribute to the high-quality development of China’s pharmaceutical and healthcare industry.”
Moving forward, Henlius will continue to uphold its philosophy of open collaboration, deepening partnerships with key players across the industry chain to jointly drive the high-quality development and integrated innovation of the biopharmaceutical industry.
About Genertec CQ Pharma
Chongqing Pharmaceutical Holdings Co., Ltd.(Known as "CQP") is a listed company on the Shenzhen Stock Exchange (stock code: 000950) with a registered capital of 1.728 billion yuan. In 2025, it joined China General Technology (Group) Holding Co., Ltd., transforming from a local state-owned enterprise to a central enterprise located in Chongqing. The company serves the entire pharmaceutical industry chain and is engaged in pharmaceutical distribution, pharmaceutical research, and development (MAH), medical device production, and investment in the pharmaceutical industry. The listed company's operating entity, Chongqing Pharmaceutical Group Co., Ltd., was formerly known as the Southwest Branch of China Pharmaceutical Company, established in 1950. It is a designated reserve unit for drugs and medical devices at both the central and local levels and one of only three national wholesale enterprises in China authorized by central government to handle narcotic drugs and class-one psychotropic drugs. It has over 230 subsidiaries and branches at all levels, with more than 14,000 employees. In 2024, its revenue was 80.562 billion yuan, its total profit was 558 million yuan with 1.48-billion-yuan taxes paid. It ranked 306th among China's top 500 enterprises in 2024 and 242nd on the 2024 Fortune China 500 list.
Currently, CQP is transforming from a traditional distribution commercial enterprise to a smart pharmaceutical supply chain service provider. We always adhere to the corporate spirit of "Devoting to the Pharmaceutical Industry and Pursuing Excellence", seizing the major opportunities in the development of the pharmaceutical and health industry, insisting on innovative development, and striving to become a first-class and internationally renowned pharmaceutical and health industry group in China, contributing to the "Healthy China" strategy.
